I mpaired visual acuity refers to decreased clarity or sharpness of vision. Impaired visual acuity is associated with decreased function and quality of life and increased risk of falls and other accidental injuries. [1] [2] [3] [4] [5] The prevalence of impaired visual acuity increases with age. 6,7 Impaired visual acuity may be unreported or unrecognized in older persons because vision changes can be relatively subtle, progress slowly over time, or occur in persons with cognitive impairment.
The US Preventive Services Task Force (USPSTF) commissioned this review to update a 2009 review 8, 9 and Recommendation Statement 10 on screening for impaired visual acuity due to uncorrected refractive errors, cataracts, and dry (atrophic) or wet (exudative) age-related macular degeneration (AMD). The USPSTF previously concluded that the evidence was insufficient to assess the balance of benefits and harms of screening for visual acuity for the improvement of outcomes in older adults (I statement).
Scope of the Review
Using established methods, 11 the USPSTF determined the scope and key questions for this review. The final research plan was posted on the USPSTF website (http://www.uspreventiveservicestaskforce .org/Page/Document/final-research-plan93/impaired-visual -acuity-in-older-adults-screening) prior to conducting the review. The analytic framework and key questions (KQs) used to guide the review are shown in Figure 1 .
Detailed methods and data for this review are contained in the full USPSTF review 12 (http://www.uspreventiveservicestaskforce .org/Page/Document/final-evidence-review147/impaired-visual -acuity-in-older-adults-screening), including search strategies, inclusion criteria, and abstraction tables; the full review also includes evidence on effectiveness of older treatments for wet AMD (laser photocoagulation and photodynamic therapy).
Data Sources and Searches
Searches were conducted in Ovid MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews from 2008 (searches in the 2009 review were conducted through July 2008) to February 2015 (eAppendix 1 in the Supplement) and reference lists. An updated search conducted on January 6, 2016, using the same databases identified no new studies that would affect the conclusions or understanding of the evidence and therefore the related USPSTF recommendation.
Study Selection
Two reviewers evaluated each study on the basis of predefined criteria. For studies on screening and diagnostic accuracy, we included studies of asymptomatic adults 65 years or older without known impaired visual acuity (based on current corrected vision) who have not sought care for evaluation of vision problems. We included randomized clinical trials (RCTs) of vision screening performed in primary care or community-based settings vs no screening, delayed screening, or usual care (eg, targeted screening) and evaluated visual acuity, vision-related quality of life, functional capacity, mortality, cognition, or harms. We included studies of diagnostic accuracy of vision screening tests, questions, or questionnaires performed in primary care or community settings. For treatment, we included RCTs of asymptomatic adults (not restricted to age Ն65 years) with mild to moderate vision impair-ment (defined as best visual acuity worse than 20/40 but better than 20/200) that evaluated effects on the outcomes described above for corrective lenses, reading aids, or photorefractive surgery due to uncorrected refractive errors; vitamin and oxidants and vascular endothelial growth factor (VEGF) inhibitors for AMD; or cataract surgery. For screening and treatment, cohort studies were included when evidence from RCTs was insufficient. We excluded studies of screening and diagnostic testing performed in specialty settings and trials of treatment in patients with visual acuity worse than 20/200 or with other causes of vision loss. The selection of literature is summarized in Figure 2 .
lenses and 41 of 75 persons (55%) eligible for referral to an ophthalmologist had clear evidence of a referral, which could have attenuated potential benefits. Other reasons for lack of benefit in the screening trials may include the high loss to follow-up in all trials, similar frequency of vision disorder detection and treatment in the screening and control groups in 1 trial, 14 use of a screening question to identify persons for further testing in 1 trial, 14 and low uptake of recommended interventions in 1 trial. 13 No study addressed harms of vision screening.
One additional screening trial did not meet inclusion criteria because it was conducted in a specialty setting. 16 It found vision screening by an optometrist in frail elderly persons increased the risk for falls (2.45 falls/patient vs 1.68 falls/patient; rate ratio, 1.57; 95% CI, 1.20-2.05) along with a non-statistically significant increased risk for fractures (10% vs 5.7%; RR, 1.74; 95% CI, 0.97-3.11) after 1 year compared with usual care. 16 Screening led to new eyeglasses or referral for further treatment for 47% of study participants. A subsequent report from this study also found no difference between groups in improvement in vision or visionrelated quality of life after 1 year. 17 
Accuracy of Screening
Key Question 3. What is the accuracy of screening for early impairment in visual acuity due to uncorrected refractive error, cataracts or age-related macular degeneration?
The 2009 USPSTF review 8 included 8 cross-sectional studies on the diagnostic accuracy of screening for impaired visual acuity in older adults ( Table 2 and eTable 2 in the Supplement). [18] [19] [20] [21] [22] [23] [24] [25] Four studies found screening questions or questionnaires had low accuracy for identifying persons with impaired visual acuity compared with the Snellen eye chart 19, 20, 23 or an ophthalmologic examination. 24 Positive likelihood ratios ranged from 1.19 to 3.23 and negative likelihood ratios ranged from 0.23 to 0.78. Four studies 18, 21, 24, 25 found no visual acuity test had both high sensitivity and specificity compared with a detailed ophthalmologic examination, resulting in positive likelihood ratios that ranged from 1.00 to 8.07 and negative likelihood ratios that ranged from 0.32 to 1.00. Two studies reported areas under the receiver operating characteristic curves of 0.66 and 0.83. 18, 21 One study found the Amsler grid had poor accuracy for identifying visual conditions (positive likelihood ratio 1.65 and negative likelihood Are there harms of treating early impairment in visual acuity? 5
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Patients identified with impairment of visual acuity
Patients without identified impairment of visual acuity "Asymptomatic" individuals are those without known impaired visual acuity (based on current corrected vision) who have not sought care for evaluation of vision problems. 1 Systematic review
Cochrane databases include the Cochrane Central Register of Controlled
Trials and the Cochrane Database of Systematic Reviews. Other sources include prior reviews, references lists, and referrals from experts. AMD indicates age-related macular degeneration; VEGF, vascular endothelial growth factor. a Studies and reviews may be included for more than 1 key question (KQ).
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Evidence Report: Screening for Impaired Visual Acuity in Older Adults ratio 0.91). 18 A study published in 1988 (n = 50) reported that 100% of patients with cataract and 75% of patients with AMD were correctly identified by a geriatrician compared with an ophthalmologist, with no false positives. 22 Three fair-quality cross-sectional studies (reported in 2 publications) published subsequent to the 2009 review evaluated the diagnostic accuracy of screening tests in primary care settings ( Table 2 and eTable 2 in the Supplement). 26, 27 Two studies (n = 180 and 200) found that a computerized vision screening tool or a flip chart version of the test were not accurate compared with a detailed eye examination. 26 Optimal sensitivity (0.80) and specificity (0.68) were observed with the combination of abnormal highcontrast visual acuity (threshold >0.19 logarithm of the minimal angle of resolution) or abnormal near visual acuity, resulting in a positive likelihood ratio of 2.5 and a negative likelihood ratio of 0.29. The flip chart instrument performed similarly, based on the low-contrast visual acuity test alone (sensitivity 0.75 and specificity 0.77, for a positive likelihood ratio of 3.26 and negative likelihood ratio of 0.32). A third study (n = 371) compared the scores on the Minimum Data Set (MDS) 2.0 Vision Patterns section against a standard visual acuity test (Early Treatment Diabetic Retinopathy Study chart) for detecting impaired visual acuity. 27 Diagnostic accuracy was poor. Using a cutoff score of 1 or greater (0 indicating adequate vision and scores of 1-3 various degrees of impairment), sensitivity of the MDS Visual Patterns section for detecting visual acuity worse than 20/40 was 0.52 and specificity 0.75, for a positive likelihood ratio of 2.11 and a negative likelihood ratio of 0.64.
Treatment Key Question 4. Does treatment of early impairment in visual acuity due to uncorrected refractive error, cataracts, or AMD lead to improved visual acuity, morbidity, mortality, vision-related quality of life, functional status, or cognition?
Uncorrected Refractive Error
We identified no new study of treatment vs no treatment for mild uncorrected refractive errors on vision, vision-related quality life, or functional outcomes. The 2009 USPSTF review 8 found that refractive lenses and refractive surgery 28 were highly effective at restoring normal or near-normal visual acuity, based on a large body of observational data and accumulated clinical experience. It also included 2 randomized trials that reported beneficial effects of corrective lenses on vision-related quality of life, but not in functional status. 29, 30 A later report from 1 of these studies, 30 published subsequent to the 2009 USPSTF review, also found no effects on function or cognitive status 31 ; however, 3 observational studies found refractive surgery was associated with improved quality of life. [32] [33] [34] 
Cataracts
The 2009 USPSTF review 8 found that more than 90% of patients undergoing cataract surgery achieved visual acuity of 20/40 or better based on observational studies. 35 It also included 1 trial that found immediate cataract surgery (within 4 weeks) decreased the risk of falls compared with routine surgery (12 months' wait): 1.00/1000 patient days vs 1.52/1000 patient days (rate ratio, 0.66; 95% CI, 0.40-0.96). 36 Two cohort studies that were not in the 2009 USPSTF review found no association of cataract surgery vs no surgery with cognitive function or quality of life after 4 months 31 and 1 year, 37 although visual acuity improved after surgery in both studies.
Dry AMD
The 2009 USPSTF review 8 included 1 large, good-quality (n = 2556) randomized trial, the Age-Related Eye Disease Study (AREDS) study. 38 AREDS reported results stratified according to the severity of AMD at baseline. Among the subgroup of patients in whom treatment is currently recommended (AREDS categories 39 The rates of AMD progression were 34% with the combination and 44% with placebo. Mortality outcomes were reported for AREDS severity categories 2, 3, and 4 (n = 3476). Zinc was also associated with a significantly decreased risk of all-cause mortality (22% vs 25%; adjusted HR, 0.83; 95% CI, 0.73-0.95) and cardiovascular mortality (adjusted RR, 0.80; 95% CI, 0.64-0.99), but there was no significant decrease in cancer mortality risk (adjusted RR, 0.84; 95% CI, 0.65-1.08).
A smaller, good-quality trial (n = 300) published since the 2009 USPSTF review found no difference between daily supplementation with fish oil capsules vs placebo in risk of visual acuity loss of 15 or more letters after 3 years (17.8% vs 16.3%; RR, 1.25; 95% CI, 0.69-2.26), although fish oil was associated with decreased risk of developing cataracts, worsening cataract, or need for cataract surgery (50.0% vs 62.5%; RR, 0.80; 95% CI, 0.64-0.99). 40 (RRs and CIs calculated based on proportions reported in the original article. 40 ) Evidence on other vitamins and minerals for dry AMD remains limited, with no clear effects on AMD progression or visual acuity ( Table 3, Table 4 , and eTable 3 in the Supplement). [41] [42] [43] [44] Wet AMD
The 2009 USPSTF review 8 included 4 good-quality trials (reported in 3 publications, n = 184 to 716) of intravitreal injection with VEGF inhibitors vs sham therapy. [45] [46] [47] In the 2009 USPSTF review, pooled results were reported separately for pegaptanib (2 trials) and ranibizumab (2 trials); both VEGF inhibitors were associated with better visual acuity outcomes vs sham injections. A meta-analysis based on all 4 of these trials found VEGF inhibitors associated with greater likelihood for a gain of 15 or more letters in visual acuity (RR, 2.92; 95% CI, 1.20 to 7.12; I 2 = 76%), but the absolute risk difference was not statistically significant (10%; 95% CI, −7% to 27%). VEGF inhibitors were associated with greater likelihood of having vision 20/200 or better vs sham injection (RR, 1.47; 95% CI, 1.30 to 1.66; I 2 = 42%; absolute risk difference, 24%; 95% CI, 12% to 37%) after 1 year (Figure 3 and Figure 4 ). Beneficial effects were also observed in the MARINA trial after 2 years. 45 One trial each found intravitreal injection with VEGF inhibitors was associated with small improvements in likelihood of driving among those driving at baseline 48 and in visionrelated function. 49 The MARINA trial found no difference between ranibizumab vs placebo in all-cause mortality (2% vs 3%; RR, 0.91; 95% CI, 0.34-2.44) or vascular mortality (1% vs 2%; RR, 0.74; 95% CI, 0.21-2.60) after 2 years. 45 In the other trials, there were no deaths 47 or mortality was not reported. 46 
Harms of Treatment
Key Question 5. Are there harms of treating early impairment in visual acuity?
Refractive Error
We identified no new study on harms of treatment for uncorrected refractive error compared with no treatment. The 2009 USPSTF review 8 included 1 small study (n = 156) that reported a higher risk of falls in older adults using multifocal lenses compared with unifocal lenses (48% vs 37%; adjusted OR, 2.29; 95% CI, 1.06-4.92). 50 Three studies reported that incidence of keratitis ranged from 0.3 to 3.6 cases per 10 000 contact lens wearers. 51-53 A meta-analysis reported rates of corneal ectasia of 0% to 0.87% based on 5 studies of laser-assisted in situ keratomileusis (LASIK) and rates of keratitis of 0% to 3.4% based on 6 studies of LASIK and 4 studies of laserassisted subepithelial keratomileusis (LASEK). 28 
Cataract
We identified no new study of harms of cataract surgery vs no surgery. The 2009 USPSTF review included 3 systematic reviews 35, 54, 55 of observational studies on harms of cataract surgery, which reported pooled rates of posterior lens opacification of 28% after 5 years and 0.13% for endophthalmitis.
AMD
We identified no new studies on harms of treatment for AMD vs no treatment. The 2009 USPSTF review 8 found use of antioxidant vitamins and mineral supplements not associated with increased risk of most adverse events. 41 One trial published subsequent to the 2009 USPSTF review found no difference between supplement use vs placebo in risk of any adverse events (93% vs 89%; RR, 1.05; 95% CI, 0.97-1.13), serious adverse events (31% vs 30%; RR, 1.04; 95% CI, 0.72-1.49), or serious ocular adverse events (8.2% vs 7.0%; RR, 1.18; 95% CI, 0.50-2.75) 40 ; one other trial published subsequent to the 2009 USPSTF review found no difference in risk of withdrawals due to adverse events (7.1% vs 2.3%; RR, 3.00; 95% CI, 0.33-28). 43 One of 2 trials found VEGF inhibitors associated with greater likelihood of withdrawal vs sham therapy 45, 46 ; there were no differences in serious or other adverse events, but estimates for those outcomes were imprecise. Table 5 summarizes the evidence reviewed for this update. We identified no new trials of vision screening vs no screening, delayed screening, or usual care. Three fair-to good-quality cluster randomized trials included in the 2009 USPSTF review 8 that enrolled more than 4700 patients found vision screening in older adults as part of a multicomponent screening intervention in primary care settings to be no more effective than no vision screening, delayed screening, or usual care. [13] [14] [15] A fourth trial found optometrist screening associated with an increased risk of falls in frail elderly individuals. 16 Conclusions regarding the suboptimal diagnostic accuracy of vision screening tests in primary care settings are also unchanged from the 2009 USPSTF review. Two new studies found that the accuracy of a computer-based screening tool was limited, d Results for the subgroup of participants with AREDS category 3 or 4 AMD; results including AREDS category 2 AMD reported in the full review. 12 e Results for participants with AREDS category 2, 3, or 4 AMD. and 1 study found that a questionnaire performed poorly as a screening test. 26, 27 The 2009 USPSTF review found that no screening question is comparable in accuracy with tests of visual acuity for identifying impaired visual acuity 19, 20, 23, 24, 56 and that the Snellen test is inaccurate compared with a detailed eye examination for identifying visual conditions identified on a comprehensive ophthalmological examination. However, the clinical importance of asymptomatic conditions identified on an ophthalmologic examination is unclear and may vary depending on the condition. For example, treatments for cataracts may still be successful after the development of impaired visual acuity, whereas impaired visual acuity due to AMD could be irreversible. Although the Snellen test remains the most widely used tool to measure visual acuity in primary care settings, no clinically relevant reference standard exists to determine its diagnostic accuracy, in part because the Snellen test is often considered the standard for assessing visual acuity in clinical practice. There remains insufficient evidence to assess the accuracy or utility of pinhole testing, the Amsler grid, visual acuity tests other than the Snellen test, physical examination, or funduscopic examination performed in primary care settings.
Discussion
Conclusions from the 2009 USPSTF review regarding the effectiveness of treatments vs no treatment for common causes of impaired visual acuity also remain unchanged. Based primarily on observational studies, a very high proportion of patients experience favorable vision-related outcomes after treatment for impaired visual acuity due to refractive error and cataracts. 8 Correction of refractive error and cataract removal are also associated with improvement in vision-related quality of life, although randomized trials and cohort studies have not shown clear effects on measures of general function, cognition, or depression. [29] [30] [31] 37, 57 For dry AMD, evidence showing the effectiveness of antioxidant vitamins and minerals for slowing progression of disease or Heterogeneity: τ 2 = 0.00; χ 2 = 0.20; P = .66; I 2 = 0% Test for overall effect: z = 8.09; P <.001 1 Test for overall effect: z = 3.96; P <.001
Heterogeneity: τ 2 = 0.00; χ 2 = 3.46; P = .18; I 2 = 42% Test for overall effect: z = 6.13; P <.001 Test for subgroup differences: χ 2 = 3.20; P = .07; I 2 = 68.8% improving visual acuity remains largely restricted to the large AREDS trial. 38, 41 Extended (10-year) follow-up from AREDS is now available, showing continued benefits. 39 Antioxidants included in the AREDS formulation have been found to be associated with congestive heart failure (vitamin E 58 ) and lung cancer in smokers (beta-carotene 59,60 ) when prescribed for prevention of cancer or cardiovascular disease, although such harms were not observed in AREDS. For wet AMD, evidence reviewed in the 2009 USPSTF review found intravitreal injection with VEGF inhibitors to be effective treatment options with a relatively low incidence of serious harms, although they may be associated with an increased risk of acute decline in visual acuity. 61 As detailed in the full review, photodynamic therapy and laser photocoagulation also appear to be associated with decreased risk of vision loss in patients with wet AMD but have been replaced as first-line therapy with VEGF inhibitors in most patients because of the risk of acute visual loss, need for retreatment (photodynamic therapy), and risk of permanent retinal damage (laser photocoagulation). 12 Our evidence review has limitations. We excluded non-English language studies, which could introduce language bias. However, we identified no relevant non-English language studies, and some research found that exclusion of non-English language studies has little effect on conclusions of reviews of noncomplementary and alternative therapies. 62 In addition, trials of therapy for dry AMD evaluated heterogeneous vitamins, antioxidants, and other supplements and could not be pooled. There were also too few randomized trials to perform reliable assessments for publication bias. 63 We identified important research gaps. Evidence indicates that screening can identify older patients with decreased visual acuity and there are effective treatments for common causes of impaired visual acuity, yet screening was not associated with improved clinical outcomes. Well-designed studies in primary care settings are needed to identify optimal methods for vision screening and to develop effective strategies for linking older adults with impaired visual acuity to appropriate care, which would help maximize the potential benefits of screening. Studies are needed on the diagnostic accuracy and utility of funduscopic examination, pinhole testing, the Amsler grid, and non-Snellen visual acuity tests in primary care settings for supplementing or replacing the Snellen visual eye chart. Evidence on effectiveness of antioxidants and vitamins for dry AMD remains largely dependent on a single large trial 38 and would be strengthened by other, well-designed trials that are also designed to adequately evaluate potential harms associated with components of the supplements, such as congestive heart failure and lung cancer risk. More studies are needed to understand the potential association between correction of refractive errors and risk of falls 16 and, if an association is present, to identify methods for mitigating these risks. Research is also needed to understand the effectiveness of new therapies that are being investigated for their effectiveness in AMD, such as statins 64 and complement inhibitors (eg, protease inhibitors). 65
Conclusions
Screening can identify persons with impaired visual acuity, and effective treatments are available for common causes of impaired visual acuity, such as uncorrected refractive error, cataracts, and dry or wet AMD. However, direct evidence found no significant difference between vision screening in older adults in primary care settings vs no screening for improving visual acuity or other clinical outcomes.
